Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tectonic Therapeutic's ROE % for the quarter that ended in Jun. 2026 was -39.25%. Tectonic Therapeutic's PB Ratio for the quarter that ended in Jun. 2026 was 2.95.
Tectonic Therapeutic's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2026 was -13.31%.
Tectonic Therapeutic ROE % Adjusted to Book Value Related Terms
Tectonic Therapeutic ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Tectonic Therapeutic's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tectonic Therapeutic ROE % Adjusted to Book Value Chart
TECX vs ZVRA, SPRY, RLMD: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, Tectonic Therapeutic's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tectonic Therapeutic ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tectonic Therapeutic's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Tectonic Therapeutic's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -13.31% mean?
Tectonic Therapeutic (TECX) has a ROE % Adjusted to Book Value of -13.31% as of Jun. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Tectonic Therapeutic and its competitors.
Is Tectonic Therapeutic's ROE % Adjusted to Book Value too high?
Tectonic Therapeutic's current ROE % Adjusted to Book Value is -13.31%. Overall, Tectonic Therapeutic has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Tectonic Therapeutic's ROE % Adjusted to Book Value compare to ZVRA and SPRY?
Tectonic Therapeutic's ROE % Adjusted to Book Value of -13.31% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Tectonic Therapeutic and its competitors. Tectonic Therapeutic's current ROE % Adjusted to Book Value is -13.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tectonic Therapeutic stock overvalued right now?
Tectonic Therapeutic (TECX) has a current ROE % Adjusted to Book Value of -13.31%. The current ROE % Adjusted to Book Value is -13.31%. Tectonic Therapeutic's overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Tectonic Therapeutic (TECX), the current ROE % Adjusted to Book Value is -13.31% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
14GF Score
Get the complete analysis for TECX
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TECX has been successfully added to your 
